(Immunity 51, 491–507.e1–e7; September 17, 2019)
The authors became aware of errors of mislabeling in some panels of this study. In Figure 2F, the schematic summarizing the experimental protocol should have identified PR8-OT-I as PR8-OVA. Meanwhile, in Figure 2G, the identities of the open square and closed square tracings were inadvertently reversed. Finally, the color coding of experimental samples in Figure 6H and the right-hand tracing in Figure 7I were incorrectly assigned. The errors were generated inadvertently during the revision process of the manuscript. This has been corrected online, and the authors sincerely apologize for these errors as well as any confusion this may have caused.
Figure 2.
Bhlhe40 Maintains Function and Survival of Trm Cells (Corrected)
Figure 6.
Identification of an Epigenetic and Metabolic Regimen Promoting CD8+ T Cell Residency Genes and Functionality (Corrected)
Figure 7.
Tubastatin A and Acetate Treatment Promotes Anti-tumor Activities of CD8+ T Cells (Corrected)
Figure 2.
Bhlhe40 Maintains Function and Survival of Trm Cells (Original)
Figure 6.
Identification of an Epigenetic and Metabolic Regimen Promoting CD8+ T Cell Residency Genes and Functionality (Original)
Figure 7.
Tubastatin A and Acetate Treatment Promotes Anti-tumor Activities of CD8+ T Cells (Original)